HAMPTON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
2024 Cantor Global Healthcare Conference on Tuesday, September 17th at 8:35 a.m. ET
TD Cowen's Chronic Urticaria Summit on Friday, September 20th at 10:00 a.m. ET
Live webcasts of the presentations will be available on the "Events & Presentations” page of the "Investors & Media" section of the Celldex website. Replays will be available for 90 days following the event.
About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit www.celldex.com.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
This email address is being protected from spambots. You need JavaScript enabled to view it.
Patrick Till
Meru Advisors
(484) 788-8560
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$25.60 |
| Daily Change: | 0.31 1.23 |
| Daily Volume: | 1,394,725 |
| Market Cap: | US$1.700B |
December 09, 2025 November 10, 2025 November 07, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
